Heart failure & cardiomyopathiesSecondary analysis
Mesenchymal Precursor Cells Reduce Mortality and Major Morbidity in Ischaemic Heart Failure with Inflammation: DREAM-HF
- Secondary analysis of the DREAM-HF randomised trial
Authors' conclusion
Ischaemic aetiology and inflammation were identified as major risk factors for MACE in control DREAM-HF patients. A single intramyocardial MPC administration produced the most significant, sustained reduction in 2-point and 3-point MACE in patients with ischaemic HFrEF and inflammation.
Study context
- Population
- Patients with heart failure with reduced ejection fraction (HFrEF) in DREAM-HF; high-risk subgroup with ischaemic HFrEF and inflammation (hs-CRP ≥2 mg/L)
- Comparison
- Mesenchymal precursor cells (MPCs) vs control
- Primary endpoint
- CV death, 2-point MACE (MI or stroke) and 3-point MACE (CV death, MI or stroke)
- Follow-up
- 30-month mean
Primary result
As reported in the abstract
2-point and 3-point MACE in ischaemic HFrEF with inflammation
MPCs vs controls: reduction in 2-point major adverse cardiovascular events (MACE)
88% (p = 0.005)
MPCs vs controls: reduction in 3-point MACE
52% (p = 0.018)
Further findings
Risk factors for CV death in control patients
- Inflammation (hs-CRP ≥2 mg/L): increased CV death risk
- 61% (p = 0.003)
- Ischaemic HFrEF aetiology: increased CV death risk
- 38% (p = 0.097)
Original publication
Mesenchymal Precursor Cells Reduce Mortality and Major Morbidity in Ischaemic Heart Failure with Inflammation: DREAM-HF. Eur J Heart Fail. Published 26 November 2024. doi:10.1002/ejhf.3522
Summarised from the published abstract; every number is checked against it